The present situation, challenges, and perspectives regarding the production and utilization of effective drugs against human Chagas disease

João Carlos Pinto Dias1,2, José Rodrigues Coura2,3 and Maria Aparecida Shikanai Yasuda2,4

[1]. Centro de Pesquisas René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, MG. [2]. Ex-Presidente da Sociedade Brasileira de Medicina Tropical, Brasília, DF. [3]. Laboratório de Doenças Parasitárias, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, RJ. [4]. Departamento de Doenças Infecciosas e Parasitárias, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP.

Dear Editor,

The first effective drugs against human Trypanosoma cruzi infection (nifurtimox, produced by Bayer, and benznidazole, produced by Roche) became available in the 1960s. Because these drugs were initially only recommended for acute cases, the international demand for their production was very low. In the subsequent 20 years, good treatment results for chronic infection in children stimulated several studies in adults with the chronic indeterminate form of the disease and even in adults in the initial stages of chronic cardiomyopathy. At the end of the twentieth century, Roche transferred the production of benznidazole to LAFEPE, a Brazilian public enterprise that received its last GMP (Certificate of Good Manufacturing Practice) in 2009. Because of the increased demand for the product and several problems with its production and distribution, the World Health Organization and the scientific community involved in research on Chagas disease have become worried in recent years about the worldwide shortage of the product, which could result in a reduced opportunity to treat millions of infected individuals.

The present situation can be summarized as follows:

News

Since 2012, three important advances in antiparasitic treatment of Chagas disease have been made: I) the availability of benznidazole after a global shortage lasting 1.5 years; II) the announcement of new presentations of benznidazole and nifurtimox, and III) the updated World Health Organization (WHO) List of Essential Medicines for children.

Benznidazole production by the Argentinean Laboratory ELEA (Laboratório Endocrinio Argentina): during two international events (the Intergovernmental Initiative of the Southern Cone for Chagas Disease Elimination, Buenos Aires, August 2012, and the International Congress for Tropical Medicine and Malaria, Rio de Janeiro, September 2012), Argentinean scientists announced the initiation of benznidazole production by ELEA through a private-public partnership. This initiative was fully endorsed by scientists and several governmental health authorities. The purpose of the Argentinean production was (a) to ensure a national supply and (b) to respond to international demand. In fact, benznidazole, the first-line treatment in most countries, is increasingly prescribed for the antiparasitic treatment of chronic human Chagas disease, with an increased demand in both endemic and non-endemic countries.

New presentations of benznidazole and nifurtimox: Two presentations of a new product, named Abarax, were registered by the Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) - National Administration of Drugs, Foods and Medical Devices of Argentina in January 2012: a pediatric double-scored 50-mg orally disintegrating tablet for administration to the entire pediatric population, ranging from newborns (because the tablet can be split into 4 pieces of 12.5mg each) to adolescents and young adults weighing 40kg, and a double-scored 100-mg orally disintegrating tablet for administration to children and adults exceeding 40kg in weight.

The active pharmaceutical ingredient is manufactured by Maprimed, a company in the same international healthcare group as ELEA, in Buenos Aires. In addition, both enterprises have been nationally and internationally certified for exhibiting the good manufacturing practices required for drug formulations.

Benznidazole 100-mg and 50-mg tablets are distributed in Latin America through the ELEA and the Pan American Health Organization (PAHO) Revolving Fund, in Spain through the Agencia Española de Medicamentos y Productos Sanitarios, and throughout the rest of the world through the ELEA and the WHO.

The original price was calculated at approximately US$60 for a bottle containing 100, 100-mg tablets and at US$40 for a bottle containing 100, 50-mg tablets. International commercialization, as in the case of the Brazilian LAFEPE, will depend on national registrations in each country or on international agreement terms involving international health agencies such as the PAHO and the WHO.

After the first year of use, the quality of Abarax has proven satisfactory with respect to adverse events and its availability in the country according to local scientists, regulatory agencies, and general physicians involved in the official project Plan de Gestión de Riesgo, led by the Argentinian Ministry of Health.

Since 2008, the only enterprise producing the drug has been LAFEPE. Several problems and difficulties were encountered,
including higher scale production; acquisition of the active ingredient that was no longer being provided by the former
producer (Roche®); delivery of the product to other countries; and high final prices after distribution in Latin America, the
United States, and Europe by Masters Limited, an international
private trade enterprise, for instance reaching €105 in Spain (a
9-fold increase above the base price). Finally, a longstanding
problem involves the lack of official certification of good
manufacturing practices by LAFEPE since February 20107-10.

The updated World Health Organization List of Essential
Medicines for children: in April 2013, the 19th Expert
Committee on the Selection and Use of Essential Medicines of
WHO discussed and approved the addition of two new
benznidazole presentations in the list of essential medicines for
children. Unlike nifurtimox, which included adult and pediatric
presentations of 120 and 30mg, respectively, there was a lack of
benznidazole presentations for people weighing less than 40kg.
The main advantage of the 12.5-mg tablet is that it can be used to
treat newborns to 2-year-old children, facilitating proper dosing
without having to break and handle pieces of larger tablets.
Additionally, the main advantage of the 50-mg tablet is that it
can be used to treat the entire pediatric population, including
adolescents and young adults3,4,8,9.

Future new drugs and drug combinations

In contrast, the expectations of scientists and public health
specialists for other new drugs to be made available in a short time
period were not met, mainly due to the apparent lack of success
of posaconazole treatment as a monotherapy in a recent clinical
trial performed in the Catalan Institute of Health and presented
at the International Congress for Tropical Medicine and Malaria
in 2012. Unfortunately, the results of future clinical assays with
drug combinations not already tested will take time to obtain1-3,7.

It also seems evident that a newer, more effective drug than
benznidazole or nifurtimox will not be available in the near term
(i.e., for 5 years or more).

Nevertheless, scientists stress that research on new drugs and
better protocols for the specific treatment of Chagas disease
(including combination therapies) should be a priority for
researchers and agencies involved in Trypanosomiasis1,3. This
strategy is the same as that adopted by the WHO Strategic and
Technical Advisory Group for Neglected Tropical Diseases at
its target-setting meeting in April 2011.

Production of quality-assured drugs

Drugs for neglected tropical diseases are key for control
and elimination. In addition to their potential to treat and cure
patients, secondary and tertiary prevention with benznidazole
and nifurtimox should be used to promote healthcare and
strengthen surveillance systems (with information on patients
and transmission routes). The treatment of patients with these
drugs should be monitored with pharmacovigilance, and studies
should be designed to improve the present dosages and protocols.

Indeed, pharmacovigilance is a critical and still neglected
area that demands urgent attention by manufacturers and
relevant official health departments7.

Another area requiring urgent attention is the need for in vivo
bioequivalence and comparative studies for both the LAFEPE
and ELEA to assess new presentations and geographical
differences in the therapeutic response to update present
management protocols because the original Roche product is
no longer available3,8.

Challenges and opportunities

Furthermore, there is a need to promote case detection,
especially due to the global shortage of benznidazole and the
consequent decrease in diagnosis and treatment worldwide. In
2013, several endemic and non-endemic countries began to
consider whether to expand the range of specific treatment for
human Chagas disease to chronic-phase cases, especially those
with indeterminate forms1-3,8.

Moreover, the WHO and several scientific institutions are
advising that the international demand for the product can be
met in the near future if the final results of the Benefit Project
suggest a concrete clinical benefit to affected individuals
classified in the first two levels of chronic cardiomyopathy.
They understand that this demand could also increase given the
increasing number of diagnoses of Chagas infection through
blood-bank screening worldwide and by the regional health
systems in Latin America6,7.

In parallel, crucial questions concerning drug costs and drug
quality must be responsibly addressed by governments, producers,
and health authorities. Especially relevant is the role of the national
regulatory agencies, which have full autonomy and independence,
to ensure the best quality drugs. There is also a concern that such
drugs may cost more in the future, which could considerably limit
their use in the poorest areas and populations that are characterized
by endemic Chagas disease. It would be ideal, and politically
more astute, if Brazil, currently the main producer of the drug
and the leader in initiatives and research on Chagas disease,
were to make the decision to guarantee the current price or to
make the drug available free of charge as a token of solidarity
with the impoverished, infected people throughout the world.

Scientists and public health specialists wish to highlight
the importance of ensuring that the global distribution of
benznidazole is secure, directly involving each national
government and respective agencies for product registration.
An alternative could be drug donations to the WHO and its regional
offices for delivery to consumer countries, as is done for other
Neglected Tropical Diseases (NTDs). This solution would
avoid the need for the costly registration of the drug in each country
and the need to renew registration every five years.

Finally, at the contextual and operative levels, recent
WHO and PAHO workshops have recognized that better and
more extensive treatment of Chagas disease urgently requires
the availability of diagnostic tools and a sufficient number of
skilled doctors, especially at the primary health-care level, and
the involvement of regional and national reference centers2,3,18.

Conclusions and recommendations

The WHO considers the regular administration of a
specific treatment against several neglected diseases to
be not only a mandatory task for improving public health but also an excellent epidemiological tool for monitoring such diseases and evaluating their control and elimination.

In the case of benznidazole, the different countries must be provided with realistic data concerning their annual demand for the product and the regularity of its production. In parallel, each country must be provided with adequate conditions to maintain control of the stocks, product evaluation, and pharmacovigilance concerning these drugs.

The sustained production of quality-assured medicines against Chagas disease is needed for at least two or three decades, given the current epidemiological scenarios of its incidence and transmission control.

The donation of quality-assured medicines, especially for congenital and pediatric cases, is timely given the necessity of promoting one of the most cost-effective interventions in the control of Chagas disease.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

REFERENCES

10. Rezende KS. Produção Brasileira de Medicamentos e Ingrediente Activo de Benznidazol. Official report to the XIX Reunión de la Comisión Intergubernamental (CI) de la Iniciativa Subregional Cono Sur de Eliminación de Triatoma infestans y Interrupción de la Transmisión Transfusional de la Tripanosomiasis Americana. Termas de Río Hondo, Argentina, Octubre 8; 2013.